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Objective: The vast majority of pancreatic cancers occurs sporadically. The
discovery of frequent variations in germline gene copy number can signifi-
cantly influence the expression levels of genes that predispose to pancreatic
adenocarcinoma. We prospectively investigated whether patients with
sporadic pancreatic adenocarcinoma share specific gene copy number
variations (CNVs) in their germline DNA.
Patients and methods: DNA samples were analyzed from peripheral
leukocytes from 72 patients with a diagnosis of sporadic pancreatic adenocar-
cinoma and from 60 controls using Affymetrix 500K array set. Multiplex
ligation-dependent probe amplification (MLPA) assay was performed using
a set of self-designed MLPA probes specific for seven target sequences.
Results: We identified a CNV-containing DNA region associated with pancre-
atic cancer risk. This region shows a deletion of 1 allele in 36 of the 72 analyzed
patients but in none of the controls. This region is of particular interest since it
contains the YTHDC2 gene encoding for a putative DNA/RNA helicase, such
protein being frequently involved in cancer susceptibility. Interestingly,
82.6% of Sicilian patients showed germline loss of one allele.
Conclusions: Our results suggest that the YTHDC2 gene could be a potential
candidate for pancreatic cancer susceptibility and a useful marker for early
detection aswell as for the development of possible new therapeutic strategies.
Keywords: copy number variations, germline alteration, pancreatic cancer susceptibility,
YTHDC2 gene
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1. Introduction
Pancreatic cancer accounts for 3% of all new cases of cancer and it is the fourth
leading cause of cancer death, with an overall 5-year survival rate of < 5%. This
incidence has not changed in nearly 50 years [1]. Pancreatic cancer is one of the
most lethal human cancers and its prognosis has not been improved despite advan-
ces in diagnostic and therapeutic strategies [2]. Environmental factors such as ciga-
rette smoking [3-5] or diseases such as diabetes [6,7], obesity [8,9] or chronic
pancreatitis [10,11] can predispose to pancreatic cancer [12]. Heritable genetic predis-
position is also sometimes involved [13,14]. The lifetime risk of pancreatic cancer is
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4.7% for first-degree relatives of patients with pancreatic
cancer and the familial risk of pancreatic cancer increases
with each affected family member [15,16]. Pancreatic cancer
can also be inherited as part of a multi-cancer syndrome
such as cancers associated with BRCA2 mutations [17,18],
Peutz-Jeghers syndrome [19], Fanconi anemia syndrome [20]
and familial atypical multiple mole-melanoma syndrome [21].
In these cases, the family pedigree reveals the occurrence of
other cancers such as breast or intestinal tumors, or melano-
mas, in addition to pancreatic tumors. However, most pancre-
atic cancers are sporadic. The molecular mechanism by
which they occur involves the same alterations in somatic
gene expression as in other cancers, which include KRAS2,
BRCA2 and TP53 mutations, telomere shortening, p21
(WAF1/CIP1) and cyclin D1 upregulations, expression of
proliferation antigens, and inactivation of p16INK4/CDKN2A
and DPC4/SMAD4 [22]. However, the mechanisms that
account for sporadic occurrence remain unknown. The
discovery of frequent variations in gene copy number (CN)
in germline DNA might further show how the sporadic
occurrence of pancreatic cancer occurs [23-26]. Such variations
can significantly influence the expression levels of involved
genes [27] and it is conceivable that some gene copy number
variations (CNVs) lead to peculiar alterations of gene
expression that predispose to pancreatic adenocarcinoma [28].
We performed a high-resolution genomic microarray anal-
ysis on germline DNA of patients with sporadic pancreatic
adenocarcinoma to determine the rate of de novo CNV and
to identify common DNA regions containing pancreatic
cancer-associated CNVs that are not detected in healthy indi-
viduals. Specific cancer-associated genes with aberrant CN
could be useful biomarkers for the early detection and for
the development of possible new therapeutic strategies.
In our study, we identified a CNV-including DNA region
that contains the YTHDC2 gene. This gene maps on chromo-
some 5 (5q22.2) and encodes for a putative ATP-dependent
RNA helicase involved in translation initiation. YTHDC2
expression was shown in tumor cell lines and TNF-a-treated
hepatocytes. However, the function of YTHDC2 in the cancer
cells and the mechanism by which the YTHDC2 gene is tran-
scribed in these cells are largely unknown [29]. In a recent
work, Tanabe et al. showed that YTHDC2 plays an important
role in cancer cell growth, the activation/recruitment of
ATF-2 and c-Jun to the YTHDC2 promoter region is necessary
for the transcription of YTHDC2, and that histone deacetylase
activity is required for the efficient expression of YTHDC2 in
both hepatocyte and hepatocellular carcinoma cells [29].
Furthermore, rare mutations in the YTHDC2 gene have been
identified in individuals with autism spectrum disorders [30].
2. Patients and methods
2.1 Sample collection
Written informed consent was obtained from all participants.
We prospectively collected 72 DNA samples from the
peripheral leukocytes of 72 patients with a diagnosis of
sporadic pancreatic adenocarcinoma. Patients with a familial
pancreatic cancer history were excluded from the study. Diag-
nosis of adenocarcinoma was confirmed by histologic analysis.
All clinical information for each enrolled patient was recorded
anonymously and coded. All DNA samples were of sufficient
quality to be genotyped. Patients were European (32 from
Brussels, 23 from Palermo, 11 from Barcelona and 6 from
Leipzig, as self-reported in the presence of the physician).
Of these patients, 39 were men and 33 were women, with a
mean age of 66 years. Sixty DNA samples from individuals
of European origin were used as controls. We used the
HapMap database as a reference [23].
2.2 CNV analysis
DNA was extracted from whole blood using the QIAamp
mini kit (Qiagen, Chatsworth, CA, USA), according to the
manufacturer’s instructions. The DNA yields and purity
were determined spectrophotometrically by measuring the
absorbance of aliquots at 260 and 280 nm. DNA was
prepared for microarray hybridization using the GeneChip
Mapping Assay Protocol (Affymetrix, Inc., Santa Clara, CA,
USA) as previously described by Pugh et al. [31]. The raw
images were analyzed using the GeneChip Operating Soft-
ware (GCOS Ver1.4.1) and GTYPE (Ver4.1) software (Affy-
metrix). We excluded samples with a genotype call rate < 93%
(http://www.biostat.jhsph.edu/~iruczins/teaching/misc/gwas/
papers/affymetrix2006.pdf) [32,33]. To assess CN alterations
we used CNAT (Ver4.0.1) software.
We set the genomic smoothing at 0.01 Mb and kept
default parameters for the other variables. CN estimates
were obtained using data from 172 HapMap samples (avail-
able online) as a reference. Chromosome X was not analyzed
to avoid gender-related complications [34]. Reproducibility
of the method was assessed by analyzing six DNAs from
patients with pancreatic adenocarcinoma in duplicate, the
second analysis confirming > 96% of CNVs obtained in the
first analysis.
2.3 Data analysis
Using SAS software and ad hoc programs, individual tables
generated by CNAT (CNATv4.0.1) were merged and probes
were ranked according to their CN value. Two lists contain-
ing the probes with CN gains (3 or 4 copies) or loss (1 or 0
copies) were generated. However, to avoid false-positive num-
ber variations due to random noise in signal intensity, we
retained only the probes that showed the same condition,
that is gain or loss, in all 72 patients. Selected probes were
merged with their respective gene annotations and physical
positions according to the NCBI human genome sequence
using the NetAffx web server (Affymetrix).
2.4 Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification (MLPA) [35]
was performed on genomic DNA isolated from peripheral
D. Fanale et al.
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blood leukocytes using an MRC Holland’s EK1 kit, according
to the manufacturer’s protocol, using self-designed synthetic
MLPA probes. The MLPA reaction was performed in
five main steps: i) DNA denaturation and hybridization of
MLPA probes; ii) ligation reaction; iii) polymerase chain reac-
tion (PCR); iv) separation of amplification products by electro-
phoresis; and v) data analysis. Following MRC-Holland
recommendations, we designed seven sets of synthetic MLPA
probes (Invitrogen, Carlsbad, CA, USA) to detect deletions
in several regions of YTHDC2 gene (Table 1). To test the qual-
ity of the ‘home-made’ probes and performedMLPA reactions,
as well as facilitate data analysis, we used ‘SALSA MLPA kit
P200-A1 Reference probemix 1’ (MRC-Holland) as a refer-
ence internal control (data not shown). Synthetic probe mix
was obtained by combining 0.8 µl of each 1 µM oligo (half-
probe) solution in a final volume of 200 µl of Tris--EDTA.
For each MLPA reaction, we used 1 µl P200 + 0.5 µl synthetic
probe mix + 1.5 µl MLPA buffer. Ligation products were
amplified by PCR. The PCR conditions were 30 sec at 95C,
30 sec at 60C and 1 min at 72C for 35 cycles; 20 min at
72C. The resulting amplification products (from 130 to
480 nt in length) were separated and analyzed by capillary
electrophoresis using ABI 3100 Genetic Analyzer (Applied
Biosystems). GeneMapper v3.5 software (Applied Biosys-
tems) was used to determine peak heights and areas, and frag-
ment sizes in base pairs (bp). Specific peaks corresponding to
each tested region of the YTHDC2 gene were identified
according to their migration in relation to size standards.
Peak heights and areas of each fragment were compared to
those of 10 non-pancreatic cancer control samples and poten-
tial heterozygous deletions were suspected when peak height
and area differed by approximately 50%. Furthermore,
duplicate assays were performed to check the accuracy of the
MLPA analysis data.
3. Results
3.1 Germline DNA analysis reveals specific CNVs in
patients with pancreatic adenocarcinoma
In this work, we used the Affymetrix platform to genotype
500,000 unique probes in patients with pancreatic adenocarci-
noma to investigate whether patients shared specific CNVs
associated with the disease that were not detected in individuals
without pancreatic cancer. Several DNA regions that showed
different CNV profiles in patients and controls were selected.
One of these, where the CNV profile was associated with
sporadic pancreatic cancer with high significance (p values
from 2.25E-11 to 6.87E-08 depending on the probe set),
was found particularly interesting. In this region, one allele
was deleted in 36 (50%) of the 72 analyzed patients, but not
in the controls. The deleted region is located on chromosome
5 (112,872,760 to 112,962,031) and its size ranges from
85,687 to 41,608 nt (Table 2). This region contains the
YTHDC2 gene (112,877,309 to 112,958,880, total size
81,571 bp). The smallest deletions detected in patients encom-
passed at least 51% of the YTHDC2 gene, including several
Table 1. ‘Home-made’ MLPA probes and target sequences*.
Probe ID YTHDC2 target sequence Probe oligonucleotide sequences‡ Total probe
size (bp)
(LPO + RPO)
LHS RHS
1 GTCCAGTCAAAGCAAAAGCGGACTG
GAGGTCATGGCAACAGTTTTTTGGGATGC
GCATCCCAAAAAACTGTT
GCCATGACC
TCCAGTCCGCTTTTGC
TTTGACTGGAC
96
2 CTGGGGCTTTAGCTCTGGTAAGAGATTG
GACAGAGTCTTCAGTACATTAAGTTGCTCA
TGAGCAACTTAATGTACT
GAAGACTCTGTCC
AATCTCTTACCAGAGC
TAAAGCCCCAG
100
3 TCCATTCCCACCAATTCATCACTTCACTGA
AACTGTACTTGCCAAGGTCAACTGTGTCCTTC
GAAGGACACAGTTGAC
CTTGGCAAGTACAGTT
TCAGTGAAGTGATGA
ATTGGTGGGAATGGA
104
4 AGGAACTGGTGACTTTCAAGTTTAGAGCTCT
GTCTTAGACCTTTCTGTGAATCCAGCTGCC
TTCAGGACA
TGTCCTGAAGGCAGC
TGGATTCACAG
AAAGGTCTA
AGACAGAGCTCTAAACT
TGAAAGTCACCAGTTCCT
112
5 CCCAATGATAGGGGTATACTAATAAACTC
CATGATTAAGCTGCTAAATTAACTAACTG
CTGATGAACTAAGTTG
CAACTTAGTTCATCA
GCAGTTAGTTAA
TTTAGCAGCTTAAT
CATGGAGTTTATTAGTA
TACCCCTATCATTGGG
116
6 AATCACACTCTGCCACAACTATTGTTTAC
TGTCTTTCTTATTAGACTATTTAATTTGATT
TTGTGTCTTAGTGCCTAA
TTAGGCACTAAGACA
CAAAATCAAATTAAA
TAGTCTAATAAG
AAAGACAGTAAACAATAG
TTGTGGCAGAGTGTGATT
120
7 CAGGGATTTTCTAGGATGTCTTCTGAGA
TTGGAAGGGAAAAGAGTCAGGACTGGGG
CTCTGCTGGACTAGGAGGAGTATTTA
TAAATACTCCTCCTA
GTCCAGCAGAGCCCC
AGTCCTGACTC
TTTTCCCTTCCAATCT
CAGAAGACATCCTAG
AAAATCCCTG
124
*MLPA probe sizes range from 96 to 124 bp.
zSequences do not include the universal primers located at the 5’ end of LPO and 3’ end of RPO.
LHS: Left hybridizing sequence; LPO: Left probe oligonucleotide; MLPA: Multiplex ligation-dependent probe amplification; RHS: Right hybridizing sequence;
RPO: Right probe oligonucleotide.
YTHDC2 in sporadic pancreatic cancer
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exons (Figure 1). Interestingly, 19 of 36 patients showing het-
erozygous deletion in the DNA region containing YTHDC2
are Sicilian (52.8%). Therefore, 82.6% (19 of 23) of patients
from Palermo had a germline loss of one allele in that gene.
Furthermore, very similar results were found when segmen-
tation analysis was performed in parallel, using the Partek
Genomics Suite (Partek GS) (data not shown).
3.2 YTHDC2 may be a potential susceptibility gene
for sporadic pancreatic adenocarcinoma
The YTHDC2 (YTH domain containing 2) gene encodes for
a 1430-amino acid protein with a theoretical molecular
weight of 160,248 Da. The YTHDC2 protein contains seven
well-conserved domains, including an R3H domain (which
binds to ssDNA or ssRNA in a sequence-specific manner), a
DEAD-like helicase superfamily domain (with helicase
activity), an ANK-repeat domain (which mediates protein--
protein interactions), another DEAD-like helicase superfamily
domain with helicase activity, a HA2 domain found in
various helicases, potentially involved in nucleic acid binding,
a DUF1605 domain systematically found toward the C-
terminus of the DEAD box-containing helicases and a YTH
domain, which likely modulates alternative splice site selection
in a concentration-dependent manner. Although its function
Table 2. Patients with sporadic pancreatic cancer showing heterozygous deletion of a DNA region containing
YTHDC2*
Chromosome Start
position
End
position
Sample
identification
Gender Age
(years)
Smoking
status
Length
(bp)
CNV
mean
‡Markers p value
5 112872760 112958447 210_M_13 F 77 F 85687 1.15 15 1.59E-04
5 112872760 112956131 PBCN-4 F 60 C 83371 0.95 14 4.14E-06
5 112872760 112956131 E4224 M 58 N 83371 1.14 14 1.53E-04
5 112872760 112950168 210_M_16 F 63 F 77408 0.91 13 1.14E-04
5 112872760 112950168 210_M_1A M 73 C 77408 1.11 13 1.66E-04
5 112872760 112950168 210_M_2A M 64 C 77408 1.09 13 4.38E-04
5 112872760 112950168 210_M_14 F 96 N 77408 1.03 13 5.93E-03
5 112884180 112956131 210_M_22 F 83 N 71951 1.06 11 1.06E-04
5 112884180 112956131 PBCN6 M 75 F 71951 1.12 11 2.50E-04
5 112884180 112956131 210_M_23 F 74 C 71951 1.19 11 2.98E-04
5 112878566 112950168 Paca6 F 66 F 71602 1.15 11 7.99E-03
5 112888603 112958447 G324 M 58 N 69844 1.13 11 1.96E-04
5 112888603 112958447 G722 M 73 C 69844 1.13 11 1.48E-03
5 112888603 112956131 E4368 M 62 F 67528 1.08 10 1.41E-05
5 112888603 112956131 210_M_10 M 70 N 67528 0.98 10 1.92E-05
5 112888603 112956131 210_M_20 M 89 F 67528 1.00 10 1.96E-05
5 112888603 112956131 210_M_6A M 61 C 67528 1.06 10 2.86E-05
5 112888603 112956131 210_M_3A F 54 N 67528 1.06 10 4.06E-05
5 112888603 112956131 210_M_5 F 52 C 67528 0.97 10 1.44E-04
5 112888603 112956131 E4301 F 59 N 67528 1.17 10 1.63E-04
5 112888603 112956131 210_M_8 F 76 N 67528 0.92 10 1.72E-04
5 112888603 112956131 G342 F 66 C 67528 1.09 10 2.05E-04
5 112888603 112956131 210_M_18 M 68 N 67528 1.09 10 2.56E-04
5 112888603 112956131 210_M_21 M 91 F 67528 1.05 10 3.57E-04
5 112888603 112956131 PBCN7 M 73 C 67528 0.99 10 4.10E-04
5 112888603 112956131 210_M_7A F 67 N 67528 0.97 10 4.84E-04
5 112888603 112956131 210_M_4 F 70 N 67528 1.03 10 9.99E-04
5 112878566 112944715 PBCN-1 M 69 F 66149 1.01 10 9.33E-04
5 112893833 112958447 PBCN-2 F 76 N 64614 0.92 10 1.14E-04
5 112893833 112958447 210_M_11 F 57 C 64614 0.87 10 2.07E-04
5 112893833 112958447 PBCN-3 M 81 N 64614 1.00 10 3.68E-04
5 112893833 112958447 G1809 F 63 F 64614 1.10 10 1.52E-03
5 112907813 112962031 210_M_17 F 80 N 54218 1.03 11 1.49E-03
5 112907813 112962031 G932 M 59 C 54218 1.16 11 6.63E-03
5 112907813 112961060 G426 M 62 F 53247 0.97 10 1.01E-03
5 112920423 112962031 G2619 M 74 N 41608 1.15 10 2.26E-03
*Chromosome = Chromosome where the segment is located; Start position = Base pair position on the chromosome at which the first marker in the segment
begins (going from top of the p-arm to the bottom of the q-arm of the chromosome); End position = Base pair position on the chromosome at which the last
marker in the segment begins; Sample identification = Sample name; Gender = Male (M) or Female (F); Smoking status = Current (C), Former (F), Never (N);
Length (bp) = Size of the segment of copy number change; CNV mean = The mean value of CNV; zMarkers = Number of SNPs + CNV markers within the
segment; p-value = p-value of CNV region.
bp: Base pairs; CNV: Copy number variation.
D. Fanale et al.
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has not yet been studied, its primary structure strongly suggests
that it is an ssRNA- or ssDNA-binding helicase. The fact that
in Drosophila the maleless gene product, which has a similar
organization (Figure 2), is a well-established helicase supports
this hypothesis [36,37]. Therefore, YTHDC2 protein is expected
to have several molecular functions such as ATP binding,
ATP-dependent helicase activity, hydrolase activity, nucleic
acid binding and nucleotide binding. Figure 3 shows some
putative interactions of YTHDC2.
3.3 MLPA analysis
Because half of the patients with pancreatic adenocarcinoma
showed a germline heterozygous deletion in a region of chro-
mosome 5 containing YTHDC2, seven gene regions were
selected for MLPA validation to confirm data previously
obtained by genome-wide CNV analysis. An MLPA assay
was performed in 36 patients showing loss of one allele,
using a set of self-designed synthetic MLPA probes specific
for seven target sequences of YTHDC2 (Table 1). We nor-
malized the samples by using peak height and area values
and comparing the patients with 10 healthy controls that
had no CNVs (deletions or amplifications) in YTHDC2, as
confirmed by a previous analysis (data not shown). Hetero-
zygous deletions were detected when peak height and area
of each fragment were reduced by approximately 50% with
respect to controls (Figure 4). MLPA analysis indicated that
YTHDC2 target sequences showed a putative germline
heterozygous deletion only in 10 of 36 (27.8%) patients
with pancreatic adenocarcinoma, partially confirming the
previously obtained CNV analysis data (Table S1). Interest-
ingly, among these, six patients are from Palermo, in part
confirming the relatively higher percentage of patients
belonging to this geographical area showing germline loss
of one allele of YTHDC2.
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Figure 1. Potentially deleted YTHDC2 gene region. A. Deletions, with at least 10 markers, detected in chromosome 5. Blue
lines are representative of the deleted region detected in each patient. The physical position of the SNPs is represented in
base pairs (bp) along chromosome 5. The underlined position, close to the exon 18, was tested using the AB kit. B.
Dendrogram of signals from cancer samples. Each probe is represented by an equal and non-proportional trait. Each row
represents a single patient tested. Each column summarizes genotyping data for the chromosomal region containing the
YTHDC2 gene. Red lines are representative of amplified segments. C. Proportional distribution of probes along chromosome
5. D. Introns and exons of the YTHDC2 gene.
YTHDC2 in sporadic pancreatic cancer
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4. Discussion
Pancreatic cancer is one of the most common fatal malignant
tumors worldwide with poor prognosis and frequent resis-
tance to conventional therapies such as radiotherapy or
chemotherapy [38-40]. CNV has recently gained considerable
interest as a source of genetic variation as it seems to play a
role in phenotypic diversity and evolution [25]. Associations
between CN changes and complex diseases were discovered
in whole-genome association studies. Furthermore, genome
analysis provided a powerful approach to test for evidence of
genetic variations within and between geographical regions
and local populations [41,42]. In a recent work, Chen et al.
reported that whereas the overall CN variant frequencies are
similar between populations, their distribution is highly
specific to the population of origin [43]. DNA samples used
in this study include those from groups of individuals from
different geographical areas so as to facilitate detection of
possible population-specific common variants. However, this
approach involves that variants that are rare and population-
restricted could be not detected because the number of indi-
viduals examined in each population is small. The germline
CNV identified in this study was found in 36 of the 72 -
analyzed patients with sporadic pancreatic adenocarcinoma,
but in none of the 60 controls, indicating that this DNA
anomaly is frequent in patients and rare in non-affected
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people. If this alteration generates a functional defect involved
in the occurrence of sporadic pancreatic cancer, its absence in
half of the patients should be explained. At least two possibil-
ities can be considered. The first is that other functional
defects, other than a defect in YTHDC2 gene, can trigger
pancreatic adenocarcinoma. Indeed, we found other CNVs
associated with pancreatic cancer with a lower frequency
that might account for such defects. The second possible
explanation is technical. We cannot exclude the possibility
that short DNA losses or other DNA anomalies involving
this region were undetectable with our approach. These
include inversions, insertions and more complex rearrange-
ments, which are found in other patients with pancreatic
cancer.
Interestingly, our genome microarray analysis detected that
19 of 23 (82.6%) patients from Palermo (Italy) showed
germline heterozygous deletion in the DNA region containing
YTHDC2. MLPA analysis further confirmed that most of
the patients showing loss of one allele in YTHDC2 (27.8%)
belongs to geographical area of Palermo (Italy). Because
CNVs may differ greatly among different populations, we
hypothesize a putative population-specific CNV in this region.
However, further investigations are needed to confirm this
hypothesis. Therefore, we suggest that YTHDC2 could be a
potential candidate for susceptibility to pancreatic cancer. To
our knowledge, this is the first report that associates a particular
CNV with susceptibility to a sporadic cancer. Interestingly,
results from a microarray analysis on familial pancreatic can-
cer [44] showed that patients with a familial history of pancreatic
cancer had a total of 56 unique germline genomic regions with
CNVs that were not present in the controls, including 31 ampli-
fications and 25 deletions. These patients did not show DNA
5000
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Figure 4. Heterozygous deletion of YTHDC2 gene. MLPA-derived amplification products were separated by electrophoresis
and peak patterns were generated from a control DNA sample (A) and a patient sample (B). Relative amounts of probe
amplification products, compared to a control DNA sample, reflect the relative copy number of seven target sequences. The
comparison between the peak heights showed a reduction by approximately 50% in patient sample with respect to control.
MLPA: Multiplex ligation-dependent probe amplification.
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anomalies in the YTHDC2 gene region, suggesting that familial
and sporadic pancreatic cancers develop through different
pathways. In addition, a truncating germline mutation in the
PALB2 gene was found in several patients with familial pancre-
atic cancer. PALB2 protein is a binding partner for BRCA2.
PALB2 mutations have previously been reported in patients
with familial breast cancer, and PALB2 is now considered to
be a susceptibility gene for pancreatic cancer [45]. An attractive
hypothesis is that genomic alterations associated with inherited
pancreatic cancer have sufficient penetrance to trigger the dis-
ease, whereas alterations associated with sporadic pancreatic
cancer require the additional influence of environmental
factors [22]. In 2009, Amundadottir et al. [46] identified an
SNP that maps to the first intron of the ABO blood group
gene, which is significantly associated with pancreatic cancer,
suggesting that people with blood group O may have a lower
risk than those with groups A or B. However, the involvement
of this SNP in susceptibility to pancreatic cancer remains to
be established.
We cannot exclude the possibility that a specific CNV is also
associated with other forms of cancer. Evaluating pancreatic
specificity by repeating the analysis with a series of DNA sam-
ples from patients with other cancers was beyond the scope of
this study. However, if cancer is the consequence of a given
series of inherited genetic imbalances, the corresponding
CNV should be found in a population of individuals chosen
at random, in a proportion corresponding to cancer occurrence
in humans (American Cancer Society 2007). We did not find
the same proportion of CNV (~20%) in our control popula-
tion, suggesting that there is no clear genetic predisposition
to cancer in general, but that more specific genetic abnormali-
ties predispose individuals to cancers of specific organs. The
CNV identified in this study, associated with susceptibility to
pancreatic adenocarcinoma, might be an example of such
specificity.
The CNV selected in this study comprises at least 51% of
the YTHDC2 gene, including several exons, indicating that
one allele is inactivated in patients with sporadic pancreatic
cancer. The YTHDC2 gene encodes for a putative helicase,
well conserved in pluricellular eukaryotes, including early
organisms. The YTHDC2 function has not yet been estab-
lished, but several proteins with similar structures are DNA
and/or RNA helicases. How the deletion of one YTHDC2
allele is a potential susceptibility factor for pancreatic adeno-
carcinoma also remains to be elucidated. However, activity
loss of several helicases has been implicated in breast and pros-
tate cancer susceptibility. Helicases are involved in DNA and
RNA metabolism, including DNA repair and recombination,
chromosomal stability, splicing and removal of proteins from
RNA. Some may act as viral receptors, others may be involved
in transcription regulation and some are involved in the initial
steps of eukaryotic translational mechanism. Many functions
are strongly associated with the cancer development.
5. Conclusions
This is a preliminary/pilot study performed on individuals
from different geographical areas in order to identify new
possible common variants in sporadic pancreatic adenocarci-
noma. However, we are looking at expanding our sample
size to carry out a research more extended and to further
confirm obtained results. The CNV reported in this study
may help increase our understanding of the physiopathology
of pancreatic cancer because gene deletions generate imbalan-
ces in the corresponding mRNA and encoded protein levels.
For genes and pathways critically dependent on a fixed
amount of a functional product, it seems likely that CNVs
could account for individual variations in disease susceptibil-
ity [47]. Also, the interaction between germline modifications
and somatic mutations could influence the phenotype. For
instance, the result of a somatic mutation occurring in a
gene whose expression is restricted to a single allele would
correspond to a knock-out. In conclusion, these data suggest
that the occurrence of pancreatic cancer involves a combina-
tion of specific somatic mutations and germline alterations.
Knowledge of the genes whose CN is altered in pancreatic
cancer could be useful for identifying patients at high risk of
developing this disease both for diagnosis and also to possibly
reveal new gene targets for preventive or curative strategies.
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